HK1141514A1 - - Google Patents
Info
- Publication number
- HK1141514A1 HK1141514A1 HK10107871.7A HK10107871A HK1141514A1 HK 1141514 A1 HK1141514 A1 HK 1141514A1 HK 10107871 A HK10107871 A HK 10107871A HK 1141514 A1 HK1141514 A1 HK 1141514A1
- Authority
- HK
- Hong Kong
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101496511A CN101676267B (zh) | 2008-09-16 | 2008-09-16 | N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1141514A1 true HK1141514A1 (is) | 2010-11-12 |
Family
ID=42029001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10107871.7A HK1141514A1 (is) | 2008-09-16 | 2010-08-18 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8362256B2 (is) |
| EP (1) | EP2327697B1 (is) |
| JP (1) | JP5649132B2 (is) |
| KR (1) | KR101674227B1 (is) |
| CN (1) | CN101676267B (is) |
| AU (1) | AU2009295168B2 (is) |
| BR (1) | BRPI0919018A2 (is) |
| CA (1) | CA2736664C (is) |
| HK (1) | HK1141514A1 (is) |
| MX (1) | MX2011002816A (is) |
| RU (1) | RU2499796C2 (is) |
| WO (1) | WO2010031266A1 (is) |
| ZA (1) | ZA201101891B (is) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104072411A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐c晶型及其制备方法和应用 |
| CN104086483A (zh) * | 2014-07-08 | 2014-10-08 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐f晶型及其制备方法和应用 |
| CN104072410B (zh) * | 2014-07-08 | 2017-02-08 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐d晶型及其制备方法和应用 |
| CN104086484B (zh) * | 2014-07-08 | 2016-05-25 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用 |
| CN104072412A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用 |
| CN104072413A (zh) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用 |
| CN105622498A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
| CN105622499A (zh) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
| CN105541708A (zh) * | 2014-10-28 | 2016-05-04 | 华东理工常熟研究院有限公司 | 硫酸阿帕替尼的新晶型 |
| WO2016168041A1 (en) | 2015-04-15 | 2016-10-20 | Dow Global Technologies Llc | Thermally insulating foam with vertically elongated cells |
| CN105801476A (zh) * | 2016-04-13 | 2016-07-27 | 上海宣创生物科技有限公司 | 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用 |
| CN106243031B (zh) * | 2016-07-26 | 2017-09-08 | 江苏恒瑞医药股份有限公司 | 一种阿帕替尼的制备方法 |
| TWI764943B (zh) | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
| US11000518B2 (en) * | 2016-12-01 | 2021-05-11 | Jiangsu Hengrui Medicine Co., Ltd. | Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer |
| CN108250138A (zh) * | 2016-12-28 | 2018-07-06 | 上海宣创生物科技有限公司 | 阿帕替尼a晶型及其制备方法和应用 |
| CN106963948A (zh) * | 2017-05-12 | 2017-07-21 | 顾艳宏 | 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用 |
| CN109381436A (zh) * | 2017-08-14 | 2019-02-26 | 江苏恒瑞医药股份有限公司 | 阿帕替尼药物组合物及其制备方法 |
| WO2019034048A1 (zh) * | 2017-08-15 | 2019-02-21 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂晶型及其制备方法 |
| CN109394685B (zh) * | 2017-08-15 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂的药物组合物及其制备方法 |
| EP3706746A4 (en) * | 2017-11-10 | 2021-12-15 | Elevar Therapeutics, Inc. | COMBINATION THERAPY WITH APATINIB FOR TREATMENT OF CANCER |
| BR112020010435A2 (pt) | 2017-12-06 | 2020-11-24 | Jiangsu Hengrui Medicine Co., Ltd. | uso de inibidor da parp no tratamento de câncer de ovário ou câncer de mama resistente à quimioterapia |
| CN109942487A (zh) * | 2017-12-21 | 2019-06-28 | 江苏恒瑞医药股份有限公司 | 一种吡啶类化合物及其制备方法、用途 |
| CN111065412B (zh) | 2017-12-29 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 |
| EP3847164A1 (en) | 2018-09-05 | 2021-07-14 | Assia Chemical Industries Ltd | New crystalline polymorphs of rivoceranib and rivoceranib mesylate |
| TW202144007A (zh) * | 2020-04-10 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種抗ｐｄ－１抗體在製備治療肢端黑色素瘤的藥物中的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| WO2004013102A1 (de) | 2002-07-31 | 2004-02-12 | Schering Aktiengesellschaft | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyrimidene |
| CN1281590C (zh) * | 2002-11-27 | 2006-10-25 | 南京凯衡科贸有限公司 | 具有抑制血管生成活性的六员氨基酰胺类衍生物 |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
-
2008
- 2008-09-16 CN CN2008101496511A patent/CN101676267B/zh active Active
-
2009
- 2009-06-11 BR BRPI0919018A patent/BRPI0919018A2/pt not_active Application Discontinuation
- 2009-06-11 WO PCT/CN2009/072239 patent/WO2010031266A1/zh active Application Filing
- 2009-06-11 RU RU2011113229/04A patent/RU2499796C2/ru active
- 2009-06-11 CA CA2736664A patent/CA2736664C/en active Active
- 2009-06-11 MX MX2011002816A patent/MX2011002816A/es active IP Right Grant
- 2009-06-11 US US13/063,850 patent/US8362256B2/en active Active
- 2009-06-11 EP EP09813987.6A patent/EP2327697B1/en active Active
- 2009-06-11 AU AU2009295168A patent/AU2009295168B2/en active Active
- 2009-06-11 KR KR1020117008504A patent/KR101674227B1/ko active IP Right Grant
- 2009-06-11 JP JP2011526364A patent/JP5649132B2/ja active Active
-
2010
- 2010-08-18 HK HK10107871.7A patent/HK1141514A1/xx unknown
-
2011
- 2011-03-11 ZA ZA2011/01891A patent/ZA201101891B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009295168B2 (en) | 2014-02-13 |
| US8362256B2 (en) | 2013-01-29 |
| MX2011002816A (es) | 2011-04-05 |
| EP2327697A4 (en) | 2012-06-06 |
| EP2327697A1 (en) | 2011-06-01 |
| AU2009295168A1 (en) | 2010-03-25 |
| JP5649132B2 (ja) | 2015-01-07 |
| ZA201101891B (en) | 2012-05-30 |
| CA2736664A1 (en) | 2010-03-25 |
| CA2736664C (en) | 2016-05-24 |
| US20110184023A1 (en) | 2011-07-28 |
| KR20110059877A (ko) | 2011-06-07 |
| WO2010031266A1 (zh) | 2010-03-25 |
| RU2011113229A (ru) | 2012-10-27 |
| EP2327697B1 (en) | 2014-03-12 |
| CN101676267B (zh) | 2012-12-26 |
| BRPI0919018A2 (pt) | 2015-12-08 |
| JP2012502885A (ja) | 2012-02-02 |
| KR101674227B1 (ko) | 2016-11-08 |
| CN101676267A (zh) | 2010-03-24 |
| RU2499796C2 (ru) | 2013-11-27 |